Novocure Is Zapping Pancreatic Cancer With Electricity. It Might Be Working.

The result was statistically significant, with a p-value below 0.001. For the non-statisticians: that means there's less than a one-in-a-thousand chance this result happened by luck.

Beyond Disease Control

Secondary results added more color. The objective response rate (meaning tumors that actually shrank meaningfully) came in at 34.6%. For context, pancreatic cancer is notoriously resistant to treatment. Getting more than a third of metastatic patients to show tumor shrinkage is noteworthy.

Median overall survival landed at 9.7 months. That compares to roughly 8.5 months in the historical control group. An extra month and change might not sound like much on paper, but in a disease this aggressive, incremental gains represent real extra time with families, holidays celebrated, conversations had. And remember, this is a Phase 2 trial with 78 patients. The confidence interval stretched from 7.9 to 12.7 months, so the true benefit could be larger (or smaller) than what the headline number suggests.

Patients wore the device for a median of about 25.6 weeks, and the safety profile was consistent with what Novocure has seen before. No scary new signals.

Why This Matters More Than Usual

Pancreatic cancer is a graveyard of failed clinical programs. Drug after drug has tried and failed to meaningfully improve survival in metastatic disease. The standard first-line options (gemcitabine/nab-paclitaxel or FOLFIRINOX) have been around for years, and while some promising targeted therapies are in development, nothing has fundamentally changed the survival curve for most patients.

Novocure's approach is compelling precisely because it's so different. This isn't another kinase inhibitor or checkpoint combo. It's a physical intervention, like adding a whole new dimension of attack to the treatment plan. The cancer cell doesn't develop resistance to electricity the way it might to a small molecule drug. At least, that's the theory.

The company also has momentum from its Phase 3 PANOVA-3 trial in locally advanced (not yet metastatic) pancreatic cancer, which showed a statistically significant improvement in overall survival. That trial, with 571 patients, was the first Phase 3 ever to demonstrate an OS benefit in unresectable locally advanced pancreatic cancer. Regulatory filings are planned based on those results.

The Skeptic's Corner

Let's pump the brakes a little. Phase 2 trials are encouraging, not conclusive. The 78-patient sample is small, and the comparison here is against historical controls, not a randomized control arm running simultaneously. Historical comparisons are tricky because patient populations, supportive care standards, and even tumor biology can shift over time. Patients who enroll in clinical trials also tend to be healthier than the general patient population, which can inflate results.

Then there's the practical question: wearing an electric field device continuously while also getting three-drug chemotherapy plus immunotherapy is a lot. Compliance and quality of life in a larger trial could look different. Novocure plans to present full results at a future medical conference, and those details will matter.

Finally, no Wall Street analyst commentary has surfaced yet. The market hasn't weighed in publicly, which means we're flying without the usual analyst chorus of upgrades and price targets. That silence is neither good nor bad; it just means the financial verdict is still pending.

What Comes Next

Novocure is building a case across multiple cancer types that TTFields deserve a seat at the oncology table beyond brain cancer. The PANOVA-3 data in locally advanced pancreatic cancer already supports regulatory filings. If PANOVA-4's results hold up under deeper scrutiny and eventually in a larger, randomized trial, it could expand the approach into metastatic disease.

For the 60,000-plus Americans diagnosed with pancreatic cancer each year, the bar is painfully low: survive a little longer, suffer a little less. Novocure's electric fields won't cure this disease anytime soon. But in a landscape where almost nothing works, "significantly better than standard chemo" is a sentence worth paying attention to.

Even if you have to strap on a weird device to get there.

Big Pharma Just Made Its Biggest Psychedelics Bet Ever

Otsuka Pharmaceutical just dropped $1.225 billion on a company built around an MDMA analog for PTSD, the biggest pharma deal the psychedelics space has ever seen. Two years after the FDA rejected Lykos' MDMA therapy, Big Pharma is betting the comeback will look very different.